Digirad Competitors

Digirad (NASDAQ:DRAD) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Digirad and Medtronic, as reported by MarketBeat.

Digirad presently has a consensus target price of $6.00, indicating a potential upside of 81.82%. Medtronic has a consensus target price of $124.2692, indicating a potential upside of 2.04%. Given Digirad's stronger consensus rating and higher possible upside, analysts plainly believe Digirad is more favorable than Medtronic.

Profitability

This table compares Digirad and Medtronic's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Digirad and Medtronic's gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Digirad.

Risk and Volatility

Digirad has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Insider and Institutional Ownership

11.4% of Digirad shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 12.5% of Digirad shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Medtronic beats Digirad on 11 of the 14 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and Digirad (NASDAQ:DRAD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Earnings and Valuation

This table compares Varian Medical Systems and Digirad's revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than Digirad.

Profitability

This table compares Varian Medical Systems and Digirad's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Varian Medical Systems and Digirad, as provided by MarketBeat.com.

Varian Medical Systems presently has a consensus price target of $159.3571, indicating a potential downside of 10.03%. Digirad has a consensus price target of $6.00, indicating a potential upside of 81.82%. Given Digirad's stronger consensus rating and higher possible upside, analysts plainly believe Digirad is more favorable than Varian Medical Systems.

Risk & Volatility

Varian Medical Systems has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500.

Insider and Institutional Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. Comparatively, 11.4% of Digirad shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by company insiders. Comparatively, 12.5% of Digirad shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Varian Medical Systems beats Digirad on 9 of the 13 factors compared between the two stocks.

Digirad (NASDAQ:DRAD) and Masimo (NASDAQ:MASI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Digirad and Masimo, as reported by MarketBeat.

Digirad currently has a consensus target price of $6.00, suggesting a potential upside of 81.82%. Masimo has a consensus target price of $272.20, suggesting a potential upside of 15.97%. Given Digirad's stronger consensus rating and higher probable upside, research analysts plainly believe Digirad is more favorable than Masimo.

Institutional and Insider Ownership

11.4% of Digirad shares are owned by institutional investors. Comparatively, 81.6% of Masimo shares are owned by institutional investors. 12.5% of Digirad shares are owned by insiders. Comparatively, 11.5% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Digirad and Masimo's top-line revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than Digirad.

Risk & Volatility

Digirad has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Digirad and Masimo's net margins, return on equity and return on assets.

Summary

Masimo beats Digirad on 10 of the 13 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Digirad (NASDAQ:DRAD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

89.1% of LivaNova shares are owned by institutional investors. Comparatively, 11.4% of Digirad shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Comparatively, 12.5% of Digirad shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

LivaNova has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.

Earnings and Valuation

This table compares LivaNova and Digirad's gross revenue, earnings per share and valuation.

Digirad has lower revenue, but higher earnings than LivaNova.

Profitability

This table compares LivaNova and Digirad's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for LivaNova and Digirad, as reported by MarketBeat.com.

LivaNova presently has a consensus target price of $67.50, suggesting a potential downside of 16.67%. Digirad has a consensus target price of $6.00, suggesting a potential upside of 81.82%. Given Digirad's stronger consensus rating and higher probable upside, analysts clearly believe Digirad is more favorable than LivaNova.

Summary

LivaNova beats Digirad on 7 of the 13 factors compared between the two stocks.

CONMED (NYSE:CNMD) and Digirad (NASDAQ:DRAD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares CONMED and Digirad's net margins, return on equity and return on assets.

Insider and Institutional Ownership

11.4% of Digirad shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Comparatively, 12.5% of Digirad shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

CONMED has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.

Earnings & Valuation

This table compares CONMED and Digirad's gross revenue, earnings per share (EPS) and valuation.

CONMED has higher revenue and earnings than Digirad.

Analyst Recommendations

This is a breakdown of recent recommendations for CONMED and Digirad, as provided by MarketBeat.

CONMED currently has a consensus price target of $104.60, suggesting a potential downside of 22.19%. Digirad has a consensus price target of $6.00, suggesting a potential upside of 81.82%. Given Digirad's stronger consensus rating and higher possible upside, analysts clearly believe Digirad is more favorable than CONMED.

Summary

CONMED beats Digirad on 8 of the 13 factors compared between the two stocks.

InMode (NASDAQ:INMD) and Digirad (NASDAQ:DRAD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 11.4% of Digirad shares are owned by institutional investors. 12.5% of Digirad shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares InMode and Digirad's revenue, earnings per share (EPS) and valuation.

InMode has higher revenue and earnings than Digirad.

Analyst Ratings

This is a summary of current recommendations for InMode and Digirad, as provided by MarketBeat.com.

InMode presently has a consensus target price of $71.50, suggesting a potential downside of 13.63%. Digirad has a consensus target price of $6.00, suggesting a potential upside of 81.82%. Given Digirad's higher probable upside, analysts clearly believe Digirad is more favorable than InMode.

Profitability

This table compares InMode and Digirad's net margins, return on equity and return on assets.

Volatility and Risk

InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.

Summary

InMode beats Digirad on 10 of the 12 factors compared between the two stocks.